New strategy may target common cancer driver with minimal side effects
Researchers have found a surprisingly common vulnerability in a broad variety of cancers and have begun designing drug compounds to exploit it, in a study led by investigators at Weill Cornell Medicine. The findings suggest the possibility of a potent, low-side-effect treatment that could benefit many patients with colorectal, breast and other cancer types.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
